(FILE 'HOME' ENTERED AT 12:04:16 ON 25 MAR 2004)

FILE 'REGISTRY' ENTERED AT 12:04:25 ON 25 MAR 2004

L1 STRUCTURE UPLOADED

L2 4 S L1

L3 4 S L1 SSS SAM

L4 74 S L1 SSS FULL

FILE 'CAPLUS, MEDLINE, USPATFULL' ENTERED AT 12:07:55 ON 25 MAR 2004

L5 89 S L4

L6 8 S L5 AND (HEPATITIS C OR HCV)

\Program Files\Stnexp\Queries\09785235-3.str





ain nodes :
6 7 8 9 10 13 14 16 17 18 19 20 21 22 23 27
ng nodes :
1 2 3 4 5 28 29 30 31 32 33
ain bonds :
1-7 2-13 2-14 3-6 5-28 6-16 8-9 9-10 16-27 17-18 17-19 17-20 21-22 21-23
ng bonds :
1-2 1-5 2-3 3-4 4-5 28-33 28-29 29-30 30-31 31-32 32-33
act/norm bonds :
1-2 1-5 1-7 2-3 2-13 2-14 3-4 4-5 5-28 8-9 9-10 16-27 17-18 17-19 17-20
21-22 21-23 28-33 28-29 29-30 30-31 31-32 32-33
act bonds :
3-6 6-16

:F,[*1]

:H,[*2],[*3]

:OH,MeO,EtO,n-PrO,i-PrO,n-BuO,i-BuO,s-BuO,t-BuO,PhO

:G1,H

tch level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 13:CLASS
14:CLASS 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom
27:CLASS 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom
neric attributes :
23:
Number of Carbon Atoms : less than 7

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 36791-04-5 REGISTRY
CN 1H-1,2,4-Triazole-3-carboxamide, 1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1-β-D-Ribofuranosyl-1,2,4-triazol-3-carboxyamide
CN 1-β-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
CN ICN 1229
CN NSC 163039
CN Ravanex
CN Rebetol
CN Ribamide
CN Ribamidil
CN Ribavarin
CN **Ribavirin**
CN Tribavirin
CN Vilona
CN Viramid
CN Virazole
FS STEREOSEARCH
DR 66510-90-5, 437710-49-1
MF C8 H12 N4 O5
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PHAR, PIRA, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: WHO

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1837 REFERENCES IN FILE CA (1907 TO DATE)
67 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1844 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L6 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:695725 CAPLUS
DOCUMENT NUMBER: 137:210908
TITLE: Nucleotides, preparation thereof, and use as inhibitors of RNA viral polymerases
INVENTOR(S): Montgomery, John A.; Babu, Yarlagadda S.; Rowland, R. Scott; Chand, Pooran
PATENT ASSIGNEE(S): Biocryst Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069903	A2	20020912	WO 2002-US6551	20020306
WO 2002069903	A3	20030227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-273342P P 20010306
US 2001-285698P P 20010424
US 2001-331323P P 20011114

OTHER SOURCE(S): MARPAT 137:210908
GI



I

AB Antiviral nucleotides I were prepared as inhibitors of RNA viral polymerases (no data), wherein X is selected from the group consisting of: O, S, N-R1, and CHR1; Y and Y' is individually selected from H, OR1, NR1R2, and N3; Z and Z' is individually selected from H, OR1, and NR1R2; R = H, monophosphate PO3R32, diphosphate P2O6R33, triphosphate P3O9R34; R1 and R2 is selected from H, alkyl, acyl, aryl which may be substituted or unsubstituted; R3 is selected from H, alkyl, alkenyl, alkynyl, aryl, acyloxyalkyl, and pivaloyloxyalkyl; B is selected from 5 or 6-substituted uracil or cytosine, pseudouracil, N-substituted pseudouracil, 2-thiouracil, 2-thiocytosine, 5- or 6-substituted 2-thiouracil and 2-thiocytosine, 6-azauracil, 5-azacytosine, 8-azapurines, and 7-aza-8-deazapurines. Substitutions may be halo-substituted alkyl, halo-substituted alkenyl, halo-substituted alkynyl, halo-substituted aryl, alkylthio, or NR1R2. When Z and Z' are H and Y or Y' is OH then B is not 5-Me uracil or cytosine; and pharmaceutically acceptable salts thereof, mono, di or triphosphate and prodrugs thereof. Thus, 1-(3'-deoxy-β-D-ribofuranosyl)-2-thiocytosine was prepared as inhibitors of RNA viral polymerases (no data).

IT **70580-87-9P 70580-88-0P**
RL: BSU (Biological study, unclassified); PNU (Preparation, unclassified); BIOL (Biological study); PREP (Preparation)
(Nucleotides, preparation thereof, and use as inhibitors of RNA viral polymerases)
RN 70580-87-9 CAPLUS
CN Cytidine, 3'-azido-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 70580-88-0 CAPLUS
CN Uridine, 3'-azido-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:555629 CAPLUS
DOCUMENT NUMBER: 137:125359
TITLE: Preparation of nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
INVENTOR(S): Carroll, Steven S.; Lafemina, Robert L.; Hall, Dawn L.; Himmelberger, Amy L.; Kuo, Lawrence C.; Maccoss, Malcolm; Olsen, David B.; Rutkowski, Carrie A.; Tomassini, Joanne E.; An, Haoyun; Bhat, Balkrishen; Bhat, Neelima; Cook, Phillip Dan; Eldrup, Anne B.; Guinosso, Charles J.; Prhavc, Marija; Prakash, Thazha P.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Isis Pharmaceuticals, Inc.
SOURCE: PCT Int. Appl., 235 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002057425	A2	20020725	WO 2002-US1531	20020118

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002147160 A1 20021010 US 2002-52318 20020118

PRIORITY APPLN. INFO.: US 2001-263313P P 20010122
US 2001-282069P P 20010406
US 2001-299320P P 20010619
US 2001-344528P P 20011025

OTHER SOURCE(S): MARPAT 137:125359

GI



I

AB The present invention provides the preparation of nucleoside compds. I, wherein B is nucleobase, Y is H, alkylcarbonyl, phosphate; R1 is H, alkenyl, alkynyl, alkyl; R2 and R3 are independently H, OH, halogen, alkyl, alkoxy, alkenyloxy, alkylthio, alkylcarbonyloxy, aryloxycrbonyl, azido, amino, alkylamino; R1 and R2 together with the carbon atom to which they are attached form a 3- to 6-membered heterocycle; R4 is H, OH, SH, NH2, alkylamino, cycloalkylamino, halogen, alkyl, alkoxy, CF3; R5 and R6 are independently H, hydroxymethyl, Me, fluoromethyl; and certain derivs. thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compds. are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of **hepatitis C** virus (**HCV**) NS5B polymerase, as inhibitors of **HCV** replication, and/or for the treatment of **hepatitis C** infection. The invention also describes pharmaceutical compns. containing such nucleoside compds. alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular **HCV** infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compds. of the present invention. Thus, 4-amino-1-(2-C-methyl-β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine was prepared as inhibitors of RNA-dependent RNA viral polymerase. Representative compds. tested in the **HCV** NS5B polymerase assay exhibited IC's less than 100 μM. The compds. of the present invention were also evaluated for their ability to affect the replication of **Hepatitis C** Virus RNA in cultured hepatoma (HuH-7) cells containing a sub-genomic **HCV** Replicon.

IT **123402-24-4P 123402-25-5P**
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nucleoside derivs. as inhibitors of RNA-dependent human RNA viral polymerase)

RN 123402-24-4 CAPLUS

CN Uridine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123402-25-5 CAPLUS
CN Cytidine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:504634 CAPLUS
DOCUMENT NUMBER: 137:57536
TITLE: Remedies for **hepatitis C**
INVENTOR(S): Morioka, Masahiko; Ubasawa, Masaru; Arai, Masaaki
PATENT ASSIGNEE(S): Mitsubishi Pharma Corporation, Japan
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051425	A1	20020704	WO 2001-JP11365	20011225
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1346724	A1	20030924	EP 2001-271879	20011225
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.:
JP 2000-394620 A 20001226
JP 2001-23542 A 20010131
JP 2001-105585 A 20010404

OTHER SOURCE(S): MARPAT 137:57536

AB Excellent remedies for **hepatitis C** which contain as the active ingredients a 3'-deoxy-3'-fluorouridine derivative and a 1-(3'-deoxy-3'-fluoro-β-L-ribofuranosyl)uracil derivative and show little side effects.

IT **57944-13-5DP**, 3'-Deoxy-3'-fluorouridine, derivs.
112668-56-1P 123402-24-4P 125217-37-0P
439579-20-1P 439579-21-2P 439579-22-3P
439579-24-5P 439579-25-6P 439579-26-7P
439579-28-9P 439579-32-5P 439579-34-7P
439579-36-9P 439579-37-0P 439579-38-1P
439579-40-5P 439579-41-6P 439579-42-7P
439579-43-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(deoxy-3'-fluorouridine derivative and a 1-(3'-deoxy-3'-fluoro--L-ribofuranosyl)uracil derivative as remedies for **hepatitis C**)

RN 57944-13-5 CAPLUS
CN Uridine, 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 112668-56-1 CAPLUS
CN Uridine, 3'-deoxy-3',5-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123402-24-4 CAPLUS
CN Uridine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 125217-37-0 CAPLUS
CN Uridine, 3'-deoxy-3'-fluoro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-20-1 CAPLUS
CN Uridine, 5-cyano-3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-21-2 CAPLUS
CN Uridine, 3'-deoxy-3'-fluoro-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-22-3 CAPLUS
CN Uridine, 5-bromo-3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-24-5 CAPLUS
CN Uridine, 3'-deoxy-3'-fluoro-2-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-25-6 CAPLUS
CN Uridine, 3'-deoxy-3'-fluoro-4-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-26-7 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-deoxy-3-fluoro-β-L-ribofuranosyl)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-28-9 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-deoxy-3-fluoro-β-L-ribofuranosyl)-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-32-5 CAPLUS
CN Uridine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3',5-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-34-7 CAPLUS
CN Uridine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-36-9 CAPLUS
CN Uridine 5'-(tetrahydrogen triphosphate), 5-cyano-3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-37-0 CAPLUS
CN Uridine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-38-1 CAPLUS
CN Uridine 5'-(tetrahydrogen triphosphate), 5-bromo-3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-40-5 CAPLUS
CN Uridine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro-2-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-41-6 CAPLUS
CN Uridine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro-4-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-42-7 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[3-deoxy-3-fluoro-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-L-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439579-43-8 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[3-deoxy-3-fluoro-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-L-ribofuranosyl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:314958 CAPLUS
DOCUMENT NUMBER: 136:340939
TITLE: Preparation of modified nucleosides for treatment of viral infections and abnormal cellular proliferation
INVENTOR(S): Stuyver, Lieven; Watanabe, Kyoichi A.
PATENT ASSIGNEE(S): Pharmasset Limited, USA
SOURCE: PCT Int. Appl., 230 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032920	A2	20020425	WO 2001-US46113	20011018
WO 2002032920	A3	20040219		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002028749	A5	20020429	AU 2002-28749	20011018
US 2003087873	A1	20030508	US 2001-45292	20011018

PRIORITY APPLN. INFO.: US 2000-241488P P 20001018
US 2001-282156P P 20010406
WO 2001-US46113 W 20011018

OTHER SOURCE(S): MARPAT 136:340939
GI



I

AB Modified nucleosides, e.g. I, wherein D is hydrogen, alkyl, acyl, monophosphate, diphosphate, triphosphate, monophosphate ester, diphosphate ester, triphosphate ester, phospholipid or amino acid; X is H, halogen, NH2, substituted amine, oxime, OH, alkoxy, SH, thioalkyl; Y is O, S, Se; R and R1 are independently H, alkyl, alkenyl, alkynyl, aryl, alkylaryl, halogen, NH2, substituted amine, oxime, hydrazine, OH, alkoxy, SH, thioalkyl, NO2, NO, CH2OH, CH2OH, ester, CONH2, amide, CN; R2 and R3 are independently H, halogen, OH, SH, OMe, SMe, NH2, NHMe, CH:CH2, CN, CH2NH2, CH2OH, CO2H; were prepared for treating a Flaviviridae (including BVDV and **HCV**), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans. This invention also provides an effective process to quantify the viral load, and in particular BVDV, **HCV** or West Nile Virus load, in a host, using real-time polymerase chain reaction ("TR-PCR"). Addnl., the invention discloses probe mols. that can fluoresce proportionally to the amount of virus present in a sample. Thus, (1'R,2'S,3'R,4'R)-1-[2,3-dihydroxy-4-(hydroxymethyl)cyclopentan-1-yl]-5-fluorocytosine was prepared and tested in vitro as antiviral and antitumor agent.

IT **60786-48-3P 415704-55-1P**
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of modified nucleosides for treatment of viral infections and abnormal cellular proliferation)

RN 60786-48-3 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-(3-azido-3-deoxy-β-D-arabinofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 415704-55-1 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-(3-azido-3-deoxy-β-L-arabinofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:171918 CAPLUS
DOCUMENT NUMBER: 136:217007
TITLE: Preparation of antiviral nucleoside derivatives as inhibitors of subgenomic **hepatitis C** virus RNA replication
INVENTOR(S): Devos, Rene; Dymock, Brian William; Hobbs, Christopher John; Jiang, Wen-rong; Martin, Joseph Armstrong; Merrett, John Herbert; Najera, Isabel; Shimma, Nobuo; Tsukuda, Takuo
PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.
SOURCE: PCT Int. Appl., 225 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018404	A2	20020307	WO 2001-EP9633	20010821
WO 2002018404	C2	20031002		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003008841	A1	20030109	US 2001-923620	20010807
AU 2001095497	A5	20020313	AU 2001-95497	20010821
EP 1315736	A2	20030604	EP 2001-976128	20010821
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013611	A	20030624	BR 2001-13611	20010821

PRIORITY APPLN. INFO.: GB 2000-21285 A 20000830
GB 2000-26611 A 20001031
WO 2001-EP9633 W 20010821

OTHER SOURCE(S): MARPAT 136:217007
GI



I



II

AB Nucleosides I , wherein R1 is hydrogen, hydroxy, alkyl, hydroxyalkyl, alkoxy, halogen, cyano, isocyano or azido; R2 is hydrogen, hydroxy, alkoxy, chlorine, bromine or iodine; R3 is hydrogen; or R2 and R3 together represent =CH2; or R2 and R3 represent fluorine; X is O, S or CH2; B is a substituted purine base, were prepared as inhibitors of subgenomic **hepatitis C** virus (**HCV**) RNA replication. Thus, nucleoside II was prepared and tested for the inhibition of **HCV** RNA replication (EC50 = 0.6 μM).

IT **26563-01-9P 125217-37-0P 129885-95-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of antiviral nucleoside derivs. as inhibitors of subgenomic **hepatitis C** virus RNA replication)

RN 26563-01-9 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-(3-deoxy-3-fluoro-β-D-xylofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 125217-37-0 CAPLUS
CN Uridine, 3'-deoxy-3'-fluoro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129885-95-6 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-deoxy-3-fluoro-β-D-xylofuranosyl)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:617773 CAPLUS
DOCUMENT NUMBER: 135:175346
TITLE: Method for the treatment or prevention of flavivirus infections using nucleoside analogues
INVENTOR(S): Ismaili, Hicham Moulay Alaoui; Cheng, Yun-Xing; Lavallee, Jean-Francois; Siddiqui, Arshad; Storer, Richard
PATENT ASSIGNEE(S): Biochem Pharma Inc., Can.
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001060315	A2	20010823	WO 2001-CA197	20010219
WO 2001060315	A3	20030116		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001035278	A5	20010827	AU 2001-35278	20010219
EP 1296690	A2	20030402	EP 2001-907276	20010219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003523978	T2	20030812	JP 2001-559414	20010219
US 2002019363	A1	20020214	US 2001-785235	20010220
NO 2002003884	A	20021017	NO 2002-3884	20020816

PRIORITY APPLN. INFO.: US 2000-183349P P 20000218
WO 2001-CA197 W 20010219

OTHER SOURCE(S): MARPAT 135:175346

AB The present invention relates to a method for the treatment or prevention of Flavivirus infections using nucleoside analogs in a host comprising administering a therapeutically effective amount of the nucleoside analog or a pharmaceutically acceptable salt thereof.

IT **70580-87-9 85708-20-9 123402-20-0**
123402-25-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for treatment or prevention of flavivirus infections using nucleoside analogs and their combination with other agents in relation to **hepatitis C** virus RNA-dependent RNA polymerase (NS5B protein))

RN 70580-87-9 CAPLUS
CN Cytidine, 3'-azido-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 85708-20-9 CAPLUS
CN Cytidine 5'-(tetrahydrogen triphosphate), 3'-azido-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123402-20-0 CAPLUS
CN Cytidine, 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123402-25-5 CAPLUS
CN Cytidine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 7 OF 8 USPATFULL on STN

ACCESSION NUMBER:	2003:11137 USPATFULL
TITLE:	Anti-**HCV** nucleoside derivatives
INVENTOR(S):	Devos, Rene, Welwyn Garden City, UNITED KINGDOM Dymock, Brian William, St. Albans, UNITED KINGDOM Hobbs, Christopher John, Hertford, UNITED KINGDOM Jiang, Wen-Rong, Welwyn Garden City, UNITED KINGDOM Martin, Joseph Armstrong, Harpenden, UNITED KINGDOM Merrett, John Herbert, Baldock, UNITED KINGDOM Najera, Isabel, St. Albans, UNITED KINGDOM Shimma, Nobuo, Chigasaki-shi, JAPAN Tsukuda, Takuo, Odawara-shi, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003008841	A1	20030109
APPLICATION INFO.:	US 2001-923620	A1	20010807 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-21285	20000830
	GB 2000-26611	20001031

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	HOFFMANN-LA ROCHE INC., PATENT LAW DEPARTMENT, 340 KINGSLAND STREET, NUTLEY, NJ, 07110
NUMBER OF CLAIMS:	49
EXEMPLARY CLAIM:	1
LINE COUNT:	4872

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention comprises novel and known purine and pyrimidine nucleoside derivatives which have been discovered to be active against **hepatitis C** virus (**HCV**). The use of these derivatives for the treatment of **HCV** infection is claimed as are the novel nucleoside derivatives disclosed herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **26563-01-9P 125217-37-0P 129885-95-6P**
(preparation of antiviral nucleoside derivs. as inhibitors of subgenomic hepatitis C virus RNA replication)

RN 26563-01-9 USPATFULL

CN 2(1H)-Pyrimidinone, 4-amino-1-(3-deoxy-3-fluoro-β-D-xylofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 125217-37-0 USPATFULL
CN Uridine, 3'-deoxy-3'-fluoro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129885-95-6 USPATFULL
CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-deoxy-3-fluoro-β-D-xylofuranosyl)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 8 OF 8 USPATFULL on STN
ACCESSION NUMBER: 2002:32541 USPATFULL
TITLE: Method for the treatment or prevention of flavivirus infections using nucleoside analogues
INVENTOR(S): Ismaili, Hicham Moulay Alaoui, Montreal, CANADA
Cheng, Yun-Xing, Dollard-des-Ormeaux, CANADA
Lavallee, Jean-Francois, Bellefeuille, CANADA
Siddiqui, Arshad, Dollard-des-Ormeaux, CANADA
Storer, Richard, Baie d'Urfe, CANADA

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002019363	A1	20020214	
APPLICATION INFO.:	US 2001-785235	A1	20010220	(9)

NUMBER	DATE

PRIORITY INFORMATION: US 2000-183349P 20000218 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MILLEN, WHITE, ZELANO & BRANIGAN, PC, 2200 CLARENDON BLVD, SUITE 1400, ARLINGTON, VA, 22201
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 1165
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method for the treatment or prevention of Flavivirus infections using nucleoside analogues in a host comprising administering a therapeutically effective amount of a compound having the formula I or a pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **70580-87-9 85708-20-9 123402-20-0**
123402-25-5
(method for treatment or prevention of flavivirus infections using nucleoside analogs and their combination with other agents in relation to hepatitis C virus RNA-dependent RNA polymerase (NS5B protein))

RN 70580-87-9 USPATFULL
CN Cytidine, 3'-azido-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 85708-20-9 USPATFULL
CN Cytidine 5'-(tetrahydrogen triphosphate), 3'-azido-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123402-20-0 USPATFULL
CN Cytidine, 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123402-25-5 USPATFULL
CN Cytidine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=>

```
FILE 'REGISTRY' ENTERED AT 11:09:10 ON 25 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   24 MAR 2004  HIGHEST RN 667234-34-6
DICTIONARY FILE UPDATES:  24 MAR 2004  HIGHEST RN 667234-34-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> E "RIBAVIRIN"/CN 25
E1            1     RIBAV/CN
E2            1     RIBAVARIN/CN
E3            1 --> RIBAVIRIN/CN
E4            1     RIBAVIRIN 2',3',5'-TRIACETATE/CN
E5            1     RIBAVIRIN 5'-DIPHOSPHATE/CN
E6            1     RIBAVIRIN 5'-MONOPHOSPHATE/CN
E7            1     RIBAVIRIN 5'-PHOSPHATE/CN
E8            1     RIBAVIRIN 5'-SULFAMATE/CN
E9            1     RIBAVIRIN 5'-TRIPHOSPHATE/CN
E10           1     RIBAVIRIN DIPHOSPHATE/CN
E11           1     RIBAVIRIN TRIBENZOATE/CN
E12           1     RIBAVIRIN TRIPHOSPHATE/CN
E13           1     RIBAVIRIN TRIPROPIONATE/CN
E14           1     RIBAVIRIN-TRIAMCINOLONE ACETONIDE MIXT./CN
E15           1     RIBAZOL K30/CN
E16           1     RIBAZOL KF 311A/CN
E17           1     RIBB (PASTEURELLA MULTOCIDA STRAIN IL1403 CLONE PM70 GENE
RIBB)/CN
E18           1     RIBBEITE/CN
E19           1     RIBBEITE (MN5(OH)2(SIO4)2)/CN
E20           1     RIBBON (DROSOPHILA MELANOGASTER GENE RIB)/CN
E21           1     RIBBON PROTEIN (CHLAMYDOMONAS REINHARDTII STRAIN 1132D- GENE
RIB43A)/CN
E22           1     RIBBON PROTEIN (CHLAMYDOMONAS REINHARDTII STRAIN GR21 GENE
RIB43A)/CN
E23           1     RIBBON-HELIX-HELIX DNA-BINDING PROTEIN ALGZ (PSEUDOMONAS
AERUGINOSA STRAIN FRD1 GENE ALGZ)/CN
E24           1     RIBBOND/CN
E25           1     RIBD (PASTEURELLA MULTOCIDA STRAIN IL1403 CLONE PM70 GENE
RIBD)/CN

=> S E3
L1            1 RIBAVIRIN/CN

=> DIS L1 1 SQIDE
THE ESTIMATED COST FOR THIS REQUEST IS 5.92 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   36791-04-5  REGISTRY
```

CN 1H-1,2,4-Triazole-3-carboxamide, 1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1-β-D-Ribofuranosyl-1,2,4-triazol-3-carboxyamide
CN 1-β-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
CN ICN 1229
CN NSC 163039
CN Ravanex
CN Rebetol
CN Ribamide
CN Ribamidil
CN Ribavarin
CN **Ribavirin**
CN Tribavirin
CN Vilona
CN Viramid
CN Virazole
FS STEREOSEARCH
DR 66510-90-5, 437710-49-1
MF C8 H12 N4 O5
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PHAR, PIRA, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: WHO

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1837 REFERENCES IN FILE CA (1907 TO DATE)
67 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1844 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 66-22-8 REGISTRY
CN 2,4(1H,3H)-Pyrimidinedione (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Uracil (8CI)**
OTHER NAMES:
CN 2,4-Dihydroxypyrimidine
CN 2,4-Dioxopyrimidine
CN 2,4-Pyrimidinediol
CN 2,4-Pyrimidinedione
CN Hybar X
CN NSC 3970
CN Pirod
CN Pyrod
FS 3D CONCORD
DR 766-19-8, 144104-68-7, 4433-21-0, 4433-24-3, 42910-77-0
MF C4 H4 N2 O2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7850 REFERENCES IN FILE CA (1907 TO DATE)
673 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
7864 REFERENCES IN FILE CAPLUS (1907 TO DATE)
5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 71-30-7 REGISTRY
CN 2(1H)-Pyrimidinone, 4-amino- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Cytosine (8CI)**
OTHER NAMES:
CN 4-Amino-2(1H)-pyrimidinone
CN 4-Amino-2-hydroxypyrimidine
CN 4-Amino-2-oxo-1,2-dihydropyrimidine
CN 4-Aminouracil
CN Cytosinimine
CN NSC 27787
FS 3D CONCORD
DR 504-05-2, 14987-28-1, 66322-75-6, 26661-23-4, 118511-36-7
MF C4 H5 N3 O
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TULSA, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6656 REFERENCES IN FILE CA (1907 TO DATE)
518 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
6669 REFERENCES IN FILE CAPLUS (1907 TO DATE)
5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

```
FILE 'REGISTRY' ENTERED AT 11:19:53 ON 25 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   24 MAR 2004  HIGHEST RN 667234-34-6
DICTIONARY FILE UPDATES:  24 MAR 2004  HIGHEST RN 667234-34-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> E "URACIL"/CN 25
E1            1     URAC 180/CN
E2            1     URAC 185/CN
E3            1 --> URACIL/CN
E4            1     URACIL B-D-ARABINOFURANOSIDE/CN
E5            1     URACIL 5,5'-THIOBIS(6-(BENZYLAMINO)-1,3-DIMETHYL-/CN
E6            1     URACIL 5-(BIS(2-IODOETHYL)AMINO)-/CN
E7            1     URACIL 5-ACETYL-3-PHENYL-2-THIO-/CN
E8            1     URACIL 5-BROMO-1-METHYL-, COMPD. WITH 9-ETHYLADENINE (1:1)/CN
E9            1     URACIL 5-ISOTHIOCYANATE/CN
E10           1     URACIL 6-AMINO-5-CHLORO-1,3-DIMETHYL-/CN
E11           1     URACIL 6-METHYL SULFONE/CN
E12           1     URACIL 634/CN
E13           1     URACIL ACRYLATE SYNTHASE/CN
E14           1     URACIL ACRYLIC ACID/CN
E15           1     URACIL ACRYLIC ACID SYNTHASE/CN
E16           1     URACIL ALLOSIDE/CN
E17           1     URACIL ARABINONUCLEOSIDE 5'-PHOSPHATE/CN
E18           1     URACIL ARABINOSIDE/CN
E19           1     URACIL ARABINOSIDE HYDROCHLORIDE/CN
E20           1     URACIL ARABINOSIDE TRIPHOSPHATE/CN
E21           1     URACIL BIS(TRIMETHYLSILYL) ETHER/CN
E22           1     URACIL CONJUGATE MONOACID/CN
E23           1     URACIL DEHYDROGENASE/CN
E24           1     URACIL DEOXYRIBOSIDE/CN
E25           1     URACIL DIHYDRATE/CN

=> S E3
L1            1 URACIL/CN

=> DIS L1 1 SQIDE
THE ESTIMATED COST FOR THIS REQUEST IS 5.92 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   66-22-8  REGISTRY
CN   2,4(1H,3H)-Pyrimidinedione (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Uracil (8CI)
OTHER NAMES:
```

CN 2,4-Dihydroxypyrimidine
CN 2,4-Dioxopyrimidine
CN 2,4-Pyrimidinediol
CN 2,4-Pyrimidinedione
CN Hybar X
CN NSC 3970
CN Pirod
CN Pyrod
FS 3D CONCORD
DR 766-19-8, 144104-68-7, 4433-21-0, 4433-24-3, 42910-77-0
MF C4 H4 N2 O2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL
      (*File contains numerically searchable property data)
    Other Sources: DSL**, EINECS**, TSCA**
      (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

          7850 REFERENCES IN FILE CA (1907 TO DATE)
           673 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
          7864 REFERENCES IN FILE CAPLUS (1907 TO DATE)
             5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> E "URACIL"/CN 25
E1   1   URAC 180/CN
E2   1   URAC 185/CN
E3   1 --> URACIL/CN
E4   1   URACIL B-D-ARABINOFURANOSIDE/CN
E5   1   URACIL 5,5'-THIOBIS(6-(BENZYLAMINO)-1,3-DIMETHYL-/CN
E6   1   URACIL 5-(BIS(2-IODOETHYL)AMINO)-/CN
E7   1   URACIL 5-ACETYL-3-PHENYL-2-THIO-/CN
E8   1   URACIL 5-BROMO-1-METHYL-, COMPD. WITH 9-ETHYLADENINE (1:1)/CN
E9   1   URACIL 5-ISOTHIOCYANATE/CN
E10   1   URACIL 6-AMINO-5-CHLORO-1,3-DIMETHYL-/CN
E11   1   URACIL 6-METHYL SULFONE/CN
E12   1   URACIL 634/CN
E13   1   URACIL ACRYLATE SYNTHASE/CN
E14   1   URACIL ACRYLIC ACID/CN
E15   1   URACIL ACRYLIC ACID SYNTHASE/CN
E16   1   URACIL ALLOSIDE/CN
E17   1   URACIL ARABINONUCLEOSIDE 5'-PHOSPHATE/CN
E18   1   URACIL ARABINOSIDE/CN
E19   1   URACIL ARABINOSIDE HYDROCHLORIDE/CN
E20   1   URACIL ARABINOSIDE TRIPHOSPHATE/CN
E21   1   URACIL BIS(TRIMETHYLSILYL) ETHER/CN
E22   1   URACIL CONJUGATE MONOACID/CN

```
E23             1       URACIL DEHYDROGENASE/CN
E24             1       URACIL DEOXYRIBOSIDE/CN
E25             1       URACIL DIHYDRATE/CN

=> E "CYTODINE"/CN 25
E1              1       CYTODEX 2/CN
E2              1       CYTODEX 3/CN
E3              0 --> CYTODINE/CN
E4              1       CYTOFE/CN
E5              1       CYTOFECTENE/CN
E6              1       CYTOFECTIN/CN
E7              1       CYTOFLAV/CN
E8              1       CYTOFLAV DIHYDRATE/CN
E9              1       CYTOFLAVIN/CN
E10             1       CYTOFOL/CN
E11             1       CYTOGAM/CN
E12             1       CYTOGEN/CN
E13             1       CYTOGENIN/CN
E14             1       CYTOGRAN/CN
E15             1       CYTOGRO/CN
E16             1       CYTOHEME/CN
E17             1       CYTOHEMIN/CN
E18             1       CYTOHESIN (MOUSE R1-ES CELL GENE CLM1 TYPE 1 ISOFORM A)/CN
E19             1       CYTOHESIN (MOUSE R1-ES CELL GENE CLM2 TYPE 2 ISOFORM A)/CN
E20             1       CYTOHESIN (MOUSE R1-ES CELL GENE CLM2 TYPE 2 ISOFORM B)/CN
E21             1       CYTOHESIN (MOUSE R1-ES CELL GENE CLM3 TYPE 3 ISOFORM A)/CN
E22             1       CYTOHESIN 1 (HUMAN CLONE B2-1 PH DOMAIN)/CN
E23             1       CYTOHESIN 1 (HUMAN CLONE B2-1 REDUCED)/CN
E24             1       CYTOHESIN 1 (HUMAN CLONE PPHCY1 140-AMINO ACID FRAGMENT)/CN
E25             1       CYTOHESIN 2 (HUMAN CLONE PJG4-5CTS18.1 PH DOMAIN)/CN

=> E "CYTOSINE"/CN 25
E1              1       CYTOSCINT ES/CN
E2              1       CYTOSEP/CN
E3              1 --> CYTOSINE/CN
E4              1       CYTOSINE (N), N,1-DIMETHYL-, MONOHYDROCHLORIDE/CN
E5              1       CYTOSINE B-D-ARABINOFURANOSIDE/CN
E6              1       CYTOSINE B-D-ARABINOFURANOSIDE-5'-TRIPHOSPHATE/CN
E7              1       CYTOSINE B-D-ARABINOSIDE/CN
E8              1       CYTOSINE B-D-ARABINOSIDE 5'-MONOPHOSPHATE/CN
E9              1       CYTOSINE 5-METHYLTRANSFERASE/CN
E10             1       CYTOSINE 5-METHYLTRANSFERASE (MOUSE MEL CELL GENE DNMT1
ISOENZYME DNMT1-B FRAGMENT)/CN
E11             1       CYTOSINE ARABINOSIDE/CN
E12             1       CYTOSINE ARABINOSIDE 3-N-OXIDE/CN
E13             1       CYTOSINE ARABINOSIDE 5'-O-(METHYL PHOSPHATE)/CN
E14             1       CYTOSINE ARABINOSIDE 5'-O-(PHENYL PHOSPHATE)/CN
E15             1       CYTOSINE ARABINOSIDE 5'-PHOSPHATE/CN
E16             1       CYTOSINE ARABINOSIDE 5'-TRIPHOSPHATE/CN
E17             1       CYTOSINE ARABINOSIDE HYDROCHLORIDE/CN
E18             1       CYTOSINE ARABINOSIDE METHYLPHOSPHONATE/CN
E19             1       CYTOSINE ARABINOSIDE MONOPHOSPHATE/CN
E20             1       CYTOSINE ARABINOSIDE PALMITATE/CN
E21             1       CYTOSINE ARABINOSIDE TRIACETATE/CN
E22             1       CYTOSINE ARABINOSIDE TRIPHOSPHATE/CN
E23             1       CYTOSINE COMPOUND WITH
2,4,6-TRIAMINO-N,N-DIETHYL-1,3,5-TRIAZINE/CN
E24             1       CYTOSINE CONJUGATE ACID/CN
E25             1       CYTOSINE DEAMINASE/CN

=> S E3
L2              1 CYTOSINE/CN

=> DIS L2 1 SQIDE
```

THE ESTIMATED COST FOR THIS REQUEST IS 5.92 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 71-30-7 REGISTRY
CN 2(1H)-Pyrimidinone, 4-amino- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Cytosine (8CI)**
OTHER NAMES:
CN 4-Amino-2(1H)-pyrimidinone
CN 4-Amino-2-hydroxypyrimidine
CN 4-Amino-2-oxo-1,2-dihydropyrimidine
CN 4-Aminouracil
CN Cytosinimine
CN NSC 27787
FS 3D CONCORD
DR 504-05-2, 14987-28-1, 66322-75-6, 26661-23-4, 118511-36-7
MF C4 H5 N3 O
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TULSA, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6656 REFERENCES IN FILE CA (1907 TO DATE)
518 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
6669 REFERENCES IN FILE CAPLUS (1907 TO DATE)
5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)